Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 24, 2026
SAP (SAP) Q2 Earnings: Cloud Backlog Surges +26% Despite EPS Miss

SAP (SAP) Q2 Earnings: Cloud Backlog Surges +26% Despite EPS Miss

Key Takeaways

  • SAP missed Wall Street estimates: Non-IFRS (non-International Financial Reporting Standards) adjusted earnings per American Depositary Receipt came in at $1.82, below the $2.03 consensus, while revenue of $11.28 billion fell short of the $11.44 billion forecast.
  • Cloud momentum remained exceptional: Cloud revenue rose 24% at constant currencies to €6.28 billion, and current cloud backlog jumped 26% at constant currencies to nearly €22.9 billion, accelerating from the first quarter.
  • Full-year operating profit guidance trimmed: Non-IFRS operating profit outlook was narrowed to €11.8–€12.2 billion, down from €11.9–€12.3 billion, reflecting the dilutive impact of the Dremio and Prior Labs acquisitions.
  • AI adoption accelerated across large deals: Management reported that artificial intelligence and SAP Business Data Cloud were embedded in more than 90% of the company's 50 largest deals during the quarter.
  • Free cash flow generation remained robust: SAP delivered €3.0 billion in free cash flow for the quarter, underscoring strong cash generation even as investment in research and development (R&D) ramped up.

Why These Results Matter

SAP's second-quarter results arrived at a pivotal moment for the German enterprise software giant. The company is navigating a multiyear transformation from traditional on-premise software licensing toward a cloud-first, AI-enabled subscription model, a shift that carries significant implications for revenue mix, profitability, and long-term valuation. With legacy software license revenue declining 32% year over year and the company's core support for on-premise systems set to end in 2027, investors are sharply focused on whether cloud growth can offset the structural decline in traditional revenue streams. The Q2 print provided a mixed picture: cloud demand indicators were undeniably strong, but profitability fell short of expectations as AI-related investment spending and acquisition costs weighed on the bottom line. To get a broader sense of how SAP stacks up against peers, I also checked this using Tickeron’s AI Screener.

Breaking Down the Q2 Numbers

SAP reported total revenue of €9.88 billion ($11.28 billion) for the second quarter ended June 30, 2026, representing a 9% increase on a reported basis and 11% growth at constant currencies. Cloud revenue was the standout performer, climbing 22% as reported and 24% at constant currencies to €6.28 billion, slightly above the company-compiled consensus of €6.26 billion. Within the cloud segment, Cloud ERP (Enterprise Resource Planning) Suite revenue rose 25%, or 27% at constant currencies, and now accounts for 88% of total cloud revenue.

On the profitability side, IFRS operating profit increased 8% to €2.64 billion, while non-IFRS operating profit grew 7% as reported, or 9% at constant currencies, to €2.74 billion. IFRS earnings per share climbed 30% to €1.89, and non-IFRS earnings per share rose 6% to €1.59. However, when converted to U.S. dollars for American Depositary Receipts, adjusted EPS of $1.82 missed the $2.03 analyst consensus by $0.21, and revenue of $11.28 billion fell $160 million short of the $11.44 billion estimate. Software license revenue declined 32% to €131 million, while software support revenue fell 8% to €2.44 billion, reflecting the ongoing structural shift away from traditional on-premise business. I also ran a quick scan with Tickeron’s AI tools to cross-check the cloud metrics against recent industry trends.

How the Market Reacted

SAP shares fell 1.79% during regular trading on July 23, closing at $146.09, as the headline EPS and revenue miss weighed on initial sentiment. However, the stock staged a notable recovery in after-hours trading, rising as much as 5–6% at various points as investors digested the stronger-than-expected cloud backlog figure and the reassurance that the profit guidance reduction stemmed from acquisition accounting rather than operating weakness. The bifurcated reaction highlights a key tension in the market's assessment of SAP: near-term earnings misses are being weighed against a powerful cloud demand narrative that suggests durable revenue growth ahead. Shares remain down roughly 48% over the past twelve months, reflecting broader software sector pressure and concerns about AI-driven disruption, making each earnings release a critical sentiment check.

Looking Ahead: Guidance and Key Factors to Monitor

SAP maintained its full-year 2026 cloud revenue guidance of €25.8 billion to €26.2 billion at constant currencies, representing 23% to 25% growth, and kept its cloud and software revenue target of €36.3 billion to €36.8 billion unchanged. Free cash flow guidance of approximately €10 billion was also reaffirmed. The sole adjustment came from non-IFRS operating profit, where the range was lowered by €0.1 billion at both ends to reflect the dilutive impact from the completed acquisitions of Dremio and Prior Labs, which management estimated would weigh on second-half operating profit by a low triple-digit million euro amount.

Several factors deserve close attention moving forward. First, the trajectory of current cloud backlog growth will be a leading indicator of future cloud revenue — management noted that backlog growth now exceeds cloud revenue growth, a reversal of the prior pattern and a bullish signal for the quarters ahead. Second, the pace of AI monetization will come under increasing scrutiny as SAP rolls out its autonomous enterprise strategy, including plans for dozens of AI assistants and more than 400 autonomous suite agents by year-end.

Investors should also monitor margin trends as R&D spending accelerates and acquisition integration costs flow through the income statement. Macroeconomic uncertainty and geopolitical tensions, particularly in the Middle East, remain wild cards that could influence enterprise spending decisions. Finally, the ongoing decline in software support revenue is expected to accelerate as the 2027 end-of-mainstream-maintenance deadline for legacy on-premise systems approaches, potentially compressing overall revenue growth rates even as cloud revenue continues to expand. From what I see, the cloud backlog acceleration stands out as the most important forward-looking detail here.

My Experience Using Tickeron’s AI Screener

When I want to put earnings data like this into a wider context, I often turn to Tickeron’s AI Screener. It lets me filter stocks and ETFs by industry, market cap, technical indicators, and AI-driven signals, which helps surface comparable names or spot patterns across the software sector without spending hours on manual screens. The tool has become a regular part of how I review quarterly reports and identify other opportunities that align with the themes I’m already tracking in names like SAP.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SAP

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


SAP's Indicator enters downward trend

The Aroon Indicator for SAP entered a downward trend on October 05, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 175 similar instances where the Aroon Indicator formed such a pattern. In 110 of the 175 cases the stock moved lower. This puts the odds of a downward move at 63%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for SAP moved out of overbought territory on September 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 16 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 44%.

The Momentum Indicator moved below the 0 level on September 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SAP as a result. In 50 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 57%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SAP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 32 of 55 cases where SAP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 58%.

The 50-day moving average for SAP moved above the 200-day moving average on September 17, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +5.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where SAP advanced for three days, in 179 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.746) is normal, around the industry mean (51.456). P/E Ratio (27.540) is within average values for comparable stocks, (82.636). Projected Growth (PEG Ratio) (1.610) is also within normal values, averaging (3.135). Dividend Yield (0.014) settles around the average of (0.011) among similar stocks. P/S Ratio (5.653) is also within normal values, averaging (69.875).

The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. SAP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 49 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SAP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Salesforce (NYSE:CRM), Shopify Inc (NASDAQ:SHOP), Uber Technologies (NYSE:UBER), ServiceNow Inc. (NYSE:NOW), Datadog (NASDAQ:DDOG), Adobe (NASDAQ:ADBE), Intuit (NASDAQ:INTU), Workday (NASDAQ:WDAY), Atlassian Corp (NASDAQ:TEAM), Autodesk (NASDAQ:ADSK).

Industry description

Packaged software comprises multiple software programs bundled together and sold as a group. For example, Microsoft Office includes multiple applications such as Excel, Word, and PowerPoint. In some cases, buying a bundled product is cheaper than purchasing each item individually[s20] . Microsoft Corporation, Oracle Corp. and Adobe are some major American packaged software makers.

Market Cap

The average market capitalization across the Packaged Software Industry is 9.9B. The market cap for tickers in the group ranges from 39 to 244.09B. SAPGF holds the highest valuation in this group at 244.09B. The lowest valued company is STIXF at 39.

High and low price notable news

The average weekly price growth across all stocks in the Packaged Software Industry was 1%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 11%. RPGL experienced the highest price growth at 180%, while WCT experienced the biggest fall at -87%.

Volume

The average weekly volume growth across all stocks in the Packaged Software Industry was -45%. For the same stocks of the Industry, the average monthly volume growth was 20% and the average quarterly volume growth was -37%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 76
Price Growth Rating: 59
SMR Rating: 77
Profit Risk Rating: 94
Seasonality Score: 6 (-100 ... +100)
View a ticker or compare two or three
SAP
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of e-business software solutions

Industry PackagedSoftware

Industry
Packaged Software
Address
Dietmar-Hopp-Allee 16
Phone
+49 6227747474
Employees
111397
Web
https://www.sap.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.